February 15, 2024

On February 14, 2024, the U.S. Food and Drug Administration (FDA) reported Smiths Medical ASD Inc.’s recall of its Medfusion model 4000 syringe pump because of issues associated with earlier software versions that may affect the alarm system, the pump, the control screen, and other parts of the pump. If undetected issues are present in the device, the device has the potential to fail and delay, interrupt, or fail to deliver the therapy per the programmed setting.

February 15, 2024

You’ve accumulated the experience, practice hours, and NCPD, and now you’re ready to take the next step in your oncology nursing career and pursue OCN® certification from the Oncology Nursing Certification Corporation (ONCC). But what about the test? If the idea of sitting for the exam fills you with fear, you’re not alone—studies show that nurses often experience moderate stress (42.1%) and mild to moderate anxiety (19.4%–25.1%) about taking tests. 

February 13, 2024

Most patients who die from cancer do not use hospice at the time of their death, ONS member and oncology nurse researcher Dena D. Shore, PhD, RN, OCN®, CNE, reported in an article published in the December 2023 issue of the Clinical Journal of Oncology Nursing (CJON). According to her literature review, cancer-related, ethnic and racial, and geographic disparities are frequently involved in delayed or nonuse of hospice care.

February 12, 2024

Although death rates have been falling 0.9% each year, cancer is the fourth leading cause of death in adolescents and young adults (AYAs), following accidents, suicide, and homicide. It is the leading cause of death from disease among AYAs assigned female at birth and second leading cause of death from disease for AYAs assigned male at birth. Approaching an AYA patient’s end of life can be difficult for patients, family, and the cancer care team, but oncology nurses can provide support for all involved.   

February 08, 2024

Infection with Clostridioides difficile (commonly referred to as C. diff; formerly Clostridium difficile) is an extreme example of a type of gut microbiome dysbiosis that can occur in patients with cancer. C. diff is a gram-positive, anaerobic, spore-forming, toxigenic bacterium, and infection is acquired via fecal-oral transmission and can cause symptoms ranging from uncomplicated diarrhea to pseudomembranous colitis and toxic megacolon.